natgillin/translations-raw huggingface dataset:
A process as in Claim 2, wherein the coupling agent system is DIAD and PPh3; and wherein the coupling agent system is present in an amount of about 1.2 molar equivalents. 
Postupak kao u Zahtjevu 2, pri čemu je sustav sredstva za spajanje DIAD i PPh3; i pri čemu je sustav sredstva za spajanje prisutan u količini od oko 1.2 molarna ekvivalenta.
The product for use as claimed in any one of claims 9 to 12 wherein the infection is caused by a bacterium selected from the group consisting of Pseudomonas spp., Staphylococcus spp., Haemophilus spp., Burkholderia spp., Streptococcus spp. 
Produkt za uporabu prema bilo kojem od zahtjeva 7 do 10, naznačen time da je infekcija uzrokovana bakterijom izabranom iz skupine koju čine bakterije Pseudomonas spp., Staphylococcus spp., Haemophilus spp., Burkholderia spp., Streptococcus spp.
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the tool attached to the free end of the third articulated telescopic segment (11) is defined by a metal detector (17). THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the tool fitted to the free end of the third articulated telescopic segment (11) is defined by an air blower system (18). 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što je alat pričvršćen na slobodni kraj trećeg uzglobljenog teleskopskog segmenta (11) definiran detektorom metala ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što je alat prigrađen na slobodni kraj trećeg uzglobljenog teleskopskog segmenta (11) definiran sustavom za puhanje zraka (18).
A compound comprising the structure shown in Formula I for use in the diagnosis or treatment of a disease by the in-vivo delivery to a cell of a therapeutic nucleic acid, one or more drug agents, or a biologically active agent, R3-(C=O)-Xaa-Z-R4 Formula I wherein 
Spoj prema formuli I za primjenu u dijagnosticiranju ili liječenju bolesti putem in vivo isporuke terapijske nukleinske kiseline, jedne ili više ljekovitih tvari ili biološki djelatne tvari u stanicu,
Method of producing fuel for energetics according to claim 5 characterized by that at least one pressure vessel (1) is placed into the liquid heat carrier (8) and next pressure vessels (1) are stepwise additionally and/or alternatively placed here, while the generated gases are continuously drawn off. 
Način za proizvodnju goriva za energetiku na temelju zahtjeva 5 do 7, naznačen time što se na početku procesa u tekući medij za prijenos topline (8) ubacuje bar jedna tlačna posuda (1) i ovdje se smještaju dodatne 1 / ili druge alternativne tlačne posude (1), pri čemu se kontinualno odvode nastali plinovi.
Peptides of the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance the stability, bioavailability, and/or affinity of the peptides. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta.
The method according to any one of paragraphs 1 to 13 which further comprises monitoring the subject during the maintenance regimen for one or more adverse side effects as indicated by elevated bilirubin or a related adverse event; and adjusting the maintenance dose. 
KSM za uporabu sukladno bilo kojem od patentnih zahtjeva od 1 do 6, pri čemu metoda nadalje sadrži nadzor subjekta tijekom režima održavanja za jednu ili više nepovoljnih nuspojava, što je indicirano povišenim bilirubinom ili u suprotnom slučaju uzročno-posljedične veze s terapijom; i prilagođavanjem doze održavanja.
The resulting crude is triturated with ice-cold water, sonicated and then filtered to afford a solid which, after drying under high vacuum, yields the titled compound. 
Dobiveni sirov proizvod se triturira s ledeno hladnom vodom, izloži ultrazvuku i zatim profiltrira, čime se dobije krutu tvar, koja nakon sušenja pod visokim vakuumom daje naslovni spoj.
The methods of this invention include administering an effective amount of a GnRH receptor antagonist, preferably in the form of a pharmaceutical composition, to a mammal in need thereof. 
Djelotvornu količinu antagonista receptora GnRH može se primijeniti u obliku farmaceutskog pripravka, na sisavcu kojem je to potrebno.
Alternatively, the reduction step can be effected using catalytic hydrogenation, for example over a Raney nickel or platinum oxide catalyst. 
Alternativno, redukcijski korak se može provesti korištenjem katalitičkog hidriranja, na primjer preko katalizatora Raney nikla ili platina oksida.
at least one non ionic surfactant; 
barem jednu ne-ionsku površinski aktivnu tvar (surfaktant);
Also there is described herein intermediates for use in forming compounds useful for cancer treatment, comprising: or wherein R2, R4, R8 and R9 are as defined in Table 1 above, P3 is a NH protecting group such as carbobenzyloxy (CBZ), and R11 and R12 are as defined in Table 1 above for R8 and R9, respectively. 
Također su ovdje opisani međuprodukti za upotrebu kod dobivanja spojeva korisnih za liječenje karcinoma, koji sadržavaju: HR P20080057 T3 gdje R», Ra, Rg 1 Ro su kao što je definirano u tabeli 1 gore, P; je NH zaštitna skupina kao npr. karbobenziloksi (CBZ), i R;:1 Rio su kao što je definirano u tabeli 1 gore za Rg odnosno Ra.
X, Y, Z and W are, independently, selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 alkyl aryl, halosubstituted C1-4 alkyl, and hydroxy substituted C1-4 alkyl; 
G F, G, H, Ki L se neovisno bira iz skupine koju čine vodik, halogen, C1-4 alkil, halogenom supstituirani C1-4 alkil, hidroksi supstituirani C1-4 alkil i C1-4 alkoksi;
WO 03/099836 describes a C-aryl glucoside compound with the following structure: This compound is reported to be an SGLT2 inhibitor and therefore to be applicable in the treatment of diabetes, complications thereof and diseases related to diabetes. 
o Et HR P20090113 T3 Objavljeno je da je ovaj spoj SGLT?2 inhibitor i prema tome je primjenjiv u liječenju dijabetesa, njegovih komplikacija 1 bolesti povezanih sa dijabetesom.
wherein R1 represents a C1-C6-alkoxygroup or —NH2, can be hydrolyzed under standard conditions in the presence of an aqueous acid or a base, to the corresponding carboxylic acid compound of Formula III 
ou, d gdje R' predstavlja C;-Cg-alkoksi skupinu ili -NH>, može biti hidroliziran u uobičajenim uvjetima u prisutnosti vodene kiseline ili baze do odgovarajućeg spoja karboksilne kiseline s formulom III a
at least 7% of the cells in the population express detectable levels of CD126; 
najmanje 7 % stanica u populaciji na svojoj površini izražava uočljive razine CD126;
adding specified amounts of NaF, AlF3, LiF, KF and Al2O3 to a melting furnace for mixing and melting to form a melt; or adding specified amounts of NaF, AlF3, LiF and KF to a melting furnace for mixing and melting, and then adding Al2O3 to obtain a melt; and raising the temperature of the melt prepared in step (1) to above 720-760°C, and then, pouring the melt into the electrolytic cell and carrying out electrolysis while the temperature is maintained at 720-760°C. 
(1) dodavanja navedenih količina NaF, AIF;, LiF, KF i AbO> u peć za topljenje radi miješanja i topljenja da se formira istopljena masa; ili dodavanja navedenih količina NaF, AIF;, LiF i KF u peć za topljenje radi miješanja i topljenja, i potom dodavanja Al2O; da se dobije istopljena masa; i (2) podizanja temperature istopljene mase pripremljene u koraku (1) do iznad 720-760"C, 1 potom, sipanja otopljenje mase u elektrolitičku stanicu 1 izvođenja elektrolize dok se temperature održava na 720-760%C.
The invention further provides a method for expressing a protein of interest in a cell under conditions of hyperosmolality comprising introducing a polynucleotide into a cell wherein said polynucleotide comprises: 
Postupak ekspresije proteina od interesa u stanici u uvjetima hiperosmolalnosti, naznačen time, da obuhvaća (A) uvođenje polinukleotida u stanicu, pri čemu taj polinukleotid sadrži:
The integrated circuit according to claim 10, wherein, when one cluster is allocated to the terminal apparatus, the control circuitry determines the resource allocation information based only on the resource allocation field. 
Postupak prijenosa prema jednom od zahtjeva 9 do 13, naznačen time da kad se dodjeljuje jedan klaster, podatak o dodjeli resursa signalizira se korištenjem dostupnih bitova u polju dodjele resursa isključivo.
Cannabinoid receptors are important in the regulation of Fc gamma receptor responses of monocytes and macrophages. 
Kanabinoid receptori bitni su za regulaciju odgovora Fc gama receptora monocita i makrofaga.
wherein the target is presented on a tumor cell or in a tumor cell environment, wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or 
pri čemu je cilj predstavljen na tumorskoj stanici ili u okruženju tumorske stanice, gdje je imunocitokin varijante IL-2 usmjeren na tumor koji se primjenjuje u kombiniranoj terapiji, naznačen time, da sadrži polipeptidne sekvence SEKV. ID BR.: 84 i SEKV.
The use of claim 28, wherein the lung infection is pneumonia. 
Uporaba iz patentnog zahtjeva 28, pri čemu infekcija pluća je upala pluća.
In addition, the article may be made virtually ashless so that the user does not have to remove any ash during use. 
Dalje, proizvod može biti napravljen praktično bez pepela tako da korisnik ne mora da odvaja nikakav pepeo za vrijeme korištenja.
represents an integer of 0 to 6, 
predstavlja cijeli broj od 0 do 6,
Background Art Background of the Invention 
(54) Naziv izuma: = ZAMRZAVANJEM OSUÅ ENA FORMULACIJA ARIPIPRAZOLA
Container bag (S) comprising: 
Vrećica kao spremnik (5) koja obuhvaća:
The controls (vehicle and Rapamycin at 2.5 mg/kg/day) or 42-O-(D-Fructosylcarbonyl)rapamycin, at 2.5 and 10 mg/kg/day were administered once daily by oral gavage to the transplant recipients (6 rats per group) starting 3 days prior to transplantation and continuing for 30 days post-transplantation. 
Kontrola (nosač i rapamicin u dozi od 2,5 mg/kg/dan) ili 42-0-(D- fruktozilkarbonil)rapamicin u dozi od 2,5 i 10 mg/kg/dan primjenjivani su jednom dnevno oralnim putem primateljima transplantata (6 štakora po grupi), počevši 3 dana prije transplantacije i nastavljajući 30 dana nakon transplantacije.
R2A is selected from the group consisting of an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl, an alkoxy substituted C1-6 alkyl and a sulfenyl substituted C1-6 alkyl; 
A je odabran iz skupine koju čine nesupstituirani C1-6alkil, halogen supstituiraniC1-6 alkil, hidroksi supstituiraniC1-6alkil, alkoksi supstituiraniC1-6 alkil i sulfenil supstituiraniC1-6 alkil;
The system of claim 1 wherein the air circulation system further comprising an air treating system (28), the air treating system (28) configured and adapted for adjusting properties of the air used for ventilation. 
Sustav temeljem zahtjeva 1 pri čemu sustav cirkulacije zraka dalje uključuje sustav tretiranja zraka (28), sustav tretiranja zraka (28) je podešen i prilagođen za prilagođavanje osobina zraka korištenog za ventilaciju.
For example, peptidic GnRH agonists, such as leuprorelin (pGlu-His-Trp-Ser-Tyr-d-Leu-Leu-Arg-Pro-NHEt), have been used to treat such conditions. 
Kao primjer, u liječenje takvih stanja upotrebljavani su peptidni agonisti GnRH, poput leuprorelina (pGlu-His-Trp-Ser- Tyr-D-Leu-Leu-Arg-Pro-NHEt).
The compound of claim 1, selected from the group consisting of: and or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, koji se bira iz skupine koju čine:
the 4-1BB signalling region is encoded by SEQ ID NO: 17 and the CD3 zeta signalling domain is encoded by SEQ ID NO:18; 
(iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
The method according to claim 7, wherein the at least one hydrophilic gelling agent is selected from at least one of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, a carbomer polymer, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin and gelatin. 
Pripravak prema zahtjevu 1 ili 2, koji dalje sadrži barem jednu hidrofilnu gelirajuću tvar, odabranu između glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol® polimera, alginatne kiseline, natrijevog alginata, kalijevog alginata, amonijevog alginata, kalcijevog alginata, agara, karagenana, karuba gume, pektina i želatine.
A solution in water comprising the following components at the following concentrations: 
Otopina u vodi, naznačena time što sadrži sljedeće komponente u sljedećim koncentracijama:
The gown according to claim 4 wherein each cord is temporarily attached to the two locations at the top portion of the gown using hook and loop devices for temporary attachment located in the shoulder area of the left and right side portions of the back portion of the gown. 
Kuta prema zahtjevu 4, naznačena time, da svaka vrpca privremeno pričvršćena sa dva mjesta na gornjem dijelu kute i to uz primjenu principa kopče i karike za privremeno pričvršćivanje, položeno u području ramena lijevog i desnog postranog dijela (3, 4) leđnog dijela kute.
A medication delivery device according to claim 1, wherein the first dose is equal to the minimum of (Cont/n) and at least one ceiling value and the second dose is equal to the maximum of (Cont/(n+1)) and at least one bottom value. 
Sukladno bilo kojoj od zaštita 1-3, uređaj za davanje lijeka je naznačen time što je prva doza jednaka najmanjem od (Cont / 1) i najmanje jedne gornje vrijednosti, a druga doza je jednaka najvećem od (Cont / (n + 1)) i najmanje jedne donje vrijednosti.
at least one pulley for each of said systems for frictioning said ropes (4); and 
- < najmanje jedan koloturnik za svaki od spomenutih sustava za trenje užadi (4); i
Preparations 1 and 2 describe preparations of reagents for S-alkylation of cysteine or the cysteine of the tripeptides and tetrapeptides (the “sulfide compounds”). 
Priprave 1 i 2 opisuju pripravu reagensa za S-alkilaciju cisteina ili cistein tripeptida i tetrapeptida (Â« sulfidni spojevi»).
A structure according to claim 4, characterized in that the support frames (20) comprise two lateral uprights (24) including a main structure (46) and a coupling plate (48). 
Konstrukcija u skladu s patentnim zahtjevom 2, naznačena time, da potporni okviri (20) sadrže dva bočna stupića (24) uključujući glavnu konstrukciju (46) i spojnu ploču (48).
FEC decoding the bit-deinterleaved Layer 1 signaling data. 
FEC dekodiranje podataka cijevi fizičke razine raspletenih bitova.
is selected from the group of alkyl, substituted alkyl, COOR29, COONR30R31; and pharmaceutically acceptable salts thereof. 
R>s je izabran iz grupe koju čine alkil, supstituirani alkil, COOR>»9, COONR3R31.
The back support device and safety bow set according to claim 1, wherein the back support device is made of wood, metal, plastic, reinforced plastic, foamed plastic or a composite material. 
Sredstvo za naslanjanje prema bilo kojem od prethodnih zahtjeva, naznačeno time, da je sredstvo za naglanjanje napravljeno od drveta, metala, plastike, pojačane plastike, pjenaste plastike, kompozitnog materijala ili od nekoliko materijala, poželjno u sustavom modularnog sklapanja, poželjno da prednja strana sredstva za naslanjanje bude presvučena mekim materijalom.
when aligned with any of SEQ ID NOs: 20 to 38 or 77 to 95 using a pairwise alignment algorithm, each moving window of x amino acids from N terminus to C terminus has at least x•y identical aligned amino acids, where x is 30 and y is 0.75, wherein the immunogenic polypeptide provides at least 70% of the protection provided in a subject by the E. coli AcfD (orf3526) protein. 
20 do 38, 58 do 76 1 77 do 95 koristeći algoritam za parno svrstavanje, svaki pokretni dio x amino kiselina od N terminala do C terminala ima barem x.y jednako poredanih amino kiselina, gdje x je 30 i y je 0.75, pri čemu imunogenski polipeptid podiže značajno sličan imuni odaziv u subjektu kao E. coli AcfD (orf3526) protein.
demonstrates the ability to block about 50-100% of the binding of GFRa3 to its ligand, artemin, with an IC50 value ranging from about 40 pM to about 15 nM; 
(ii) pokazuje sposobnost blokiranja oko 50-100 % vezivanja GFRa3 za njegov ligand, artemin, uz vrijednost ICs9 u rasponu od 40 pM do oko 15 nM;
The solvent is removed in vacuo and the resulting solid is recrystallised from ethanol/water to yield the titled product. 
Otapalo se odstrani u vakuumu i dobivenu krutu tvar se prekristalizira iz etanol/vode, čime se dobije naslovni proizvod.
The substance may be isolated from its enantiomer or synthesized de novo. A second aspect of the present invention provides a method of treating psychological and psychiatric symptoms in a subject having a NE receptor. The method includes administering a substance (such as d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof) to a subject under conditions effective for the substance to bind to the NE receptor of the subject and thereby relieve the subject from psychological symptoms such as depression, anxiety, fatigue, mood instability including pseudo-bulbar affect. 
HR P20181481 T1 PATENTNI ZAHTJEVI Tvar koja je izabrana iz skupine koja se sastoji od d-metadona, d-metadola, d-alfa-acetilmetadola, d-alfa- normetadola, I-alfa-normetadola, njihovih farmaceutski prihvatljivih soli, i njihovih smjesa za uporabu u liječenju psiholoških i psihijatrijskih simptoma kod subjekta, pri čemu psihološki simptomi uključuju depresiju, anksioznost, umor, i/ili nestabilnost raspoloženja, uključujući pseudo-bulbarni utjecaj; pri čemu je tvar izolirana iz njegovog enantiomera ili sintetizirana de novo; i pri čemu se tvar može vezati na: receptor NMDA (N-metil-D-aspartat) subjekta i/ili receptor NE (norepinefrin) subjekta.
2, and the modification consists of a substitution at amino acid residue C31 selected from the group consisting of C31I, C31M, C31F, C31V, C31W, C31Y, C31R and C31H. 
2; i modifikacija se sastoji od supstitucije na aminokiselinskom ostatku C31 izabranom iz grupe koju čine C31I, C31M, C31F, C31V, C31W, C31Y, C31R i C31H.
a non-transparent connection. 
ne-transparentna veza.
The attenuated virus of claim 1, wherein the nucleotide sequence of the modified virus protein-encoding sequence is less than 90% identical to the nucleotide sequence of the protein-encoding sequence of the parent virus. 
sekvenca koja kodira modificirani protein je manje od 90 % identična sekvenci koja kodira protein matičnog virusa i sekvenca koja kodira modificirani protein i sekvenca koja kodira matični protein kodiraju isti protein;
Lasting clinical symptoms are induced by degradation of the myelin sheath and deterioration of the oligodendrocyte resulting in a plurality of nerve injuries (Fu et al., Brain 121, 103-113. 
Trajni klinički simptomi se javljaju degradacijom mijelinske ovojnice i deterioracijom oligodendrocita što rezultira u mnogobrojnim oštećenjima živaca (Fu et al., Brain 121, 103-113.
is absent, hydrogen, halogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C1-C6 alkyl and the C1-C6 alkoxy are each optionally substituted by one, two or three R14 groups, and further wherein the C3-C7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R15 groups; 
R? je odsutan, vodik, halogen, Ci-Cg alkil, C2-C4 alkinil, C,-C4 alkoksi, C3-C, cikloalkil ili 3-7-eročlani heterocikloalkil, gdje svaki od Ci-Cg alkila i C,-Cg alkoksi može biti supstituiran s jednom, dvije ili tri skupine R'", te gdje dodatno svaki od C3-C; cikloalkila i 3-7-eročlanog heterocikloalkila može biti supstituiran s jednom, dvije ili tri skupine R'?;
a suction system for pumping sludge from the bottom to the water surface to e.g. a barge moored alongside the vessel, the suction system having an at least one lower suction pipe section for winning sludge at a suction location at the bottom, 
- usisni sustav, namijenjen crpljenju mulja s dna do površine vode, do primjerice teglenice imobilizirane uz plovilo, gdje usisni sustav ima najmanje jedan donji dio usisne cijevi za izvlačenje mulja na mjestu usisavanja na dnu,
the gene expression profile for the test sample is obtained using microarray analysis with probes specific for an expression product of each of said intrinsic genes; or 
(ill) profil ekspresije gena za ispitivani uzorak se dobiva analizom na mikročipu, uz pomoć sondi specifičnih za produkt ekspresije svakog od navedenih intrinzičnih gena; ili
PCT/CN2012/085023, filed Nov. 22, 2012, and International Application No. 
(31) Broj prve prijave: PCT/CN2012/085023 (32) Datum podnošenja prve prijave: 22.11.2012.
Panel according to at least one of the preceding claims, wherein the board (12) is a particle board or a HDF board or a gypsum board or an OSB board. 
Postupak prema zahtjevu 11, naznačen time što ploča je ploča od čestica, HDF ploča, ploča od gipsa, WPC (kompozit drvo plastika) ili OSB ploča.
The transmitter of claim 1, wherein the first FEC encoder comprises: 
Prijenosnik iz patentnog zahtjeva 1, pri čemu prvi FEC koder obuhvaća:
VBP15 or VBP6 for use according to Claim 1, wherein the compound is VBP15. 
VBPISili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je spoj VBP15.
The composition of claim 1 wherein the surfactant has an HLB value of about 8 or higher than 8. 
Sastav prema patentnom zahtjevu 3, naznačen time, da površinski aktivna tvar ima HLB-vrijednost od 8 ili veću od 8.
Ortho 125Iodination of phenols—This procedure allows for the incorporation of 125I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labeled Compd Radiopharm. 
B. Orto '"I jodiranje fenola - Taj postupak dozvoljava ugradnju '"I na orto položaj fenola kako su to objavili Collier, T.L. i sur. u J.Labeled Compd Radiopharm.
The compositions of the invention preferably comprise caspofungin calculated as caspofungin base in a concentration of about 0.1 mg/ml to about 500 mg/ml, such as about 10 mg/ml to about 200 mg/ml, preferably about 20 mg/ml to about 60 mg/ml, most preferably 42 mg/ml in case the composition is a liquid composition, i.e. additionally comprises e.g. water. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da obuhvaća 0,1 mg/ml do 500 mg/ml, poželjno 20 mg/ml do 60 mg/ml kaspofungina, računajući kao kaspofungin bazu, 10 mg/ml do 200 mg/ml, poželjno 40 mg/ml do 60 mg/ml pomoćnog sredstva, koje je punilo za povećanje mase, poželjno mješavina šećernih punila za povećanje mase, učinkovitog za tvorbu liofiliziranog kolača, i vodu.
According to the present invention then, new and useful chemical compounds for use in cancer treatment are provided having the formulas: 
U skladu s predmetnim izumom predviđeni su dakle novi i korisni kemijski spojevi za upotrebu u liječenju karcinoma koji imaju sljedeću formulu:
The compound according to claim 1 wherein n = 1 and R4 is OH or =O with the meaning of carbonyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što n = 1, a R* je OH ili =0, sa značenjem karbonila.